FORMA Therapeutics Appoints Robert Forrester Chief Operating Officer

FORMA Therapeutics Appoints Robert Forrester Chief Operating Officer

 - Brings Extensive Experience in Operations, Strategy, Corporate Development and Fundraising to FORMA-

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2010 - FORMA Therapeutics announced today that Robert Forrester has been appointed Chief Operating Officer. Mr. Forrester brings to FORMA extensive experience in corporate operations and finance, corporate development, and public and private fundraising.

"FORMA has been extremely successful in attracting capital and world class partners in the short amount of time since its founding," said Mr. Forrester. "I look forward to being involved in continuing these corporate development efforts, and believe that the Company's fully integrated drug discovery platform will continue to be very attractive to partners and investors due to its potential for unlocking previously intractable targets, particularly for oncology."

"As FORMA continues to advance our breakthrough oncology pipeline and engage partners surrounding our discovery technologies and product candidates, Robert's extensive life sciences and corporate development expertise will be important," said Steven Tregay, CEO of FORMA. "Most recently, Robert was instrumental in structuring, negotiating and closing CombinatoRx's merger with Neuromed, guiding the company through an initial public offering, and forging several research and product development collaborations. His background will strengthen and complement the existing FORMA management team."


 

Before joining FORMA, Mr. Forrester served as the Interim President and CEO, and CFO of CombinatoRx from 2004 until 2010. Prior to joining CombinatoRx, Mr. Forrester served as Senior Vice President, Finance and Corporate Development at Coley Pharmaceutical Group (acquired by Pfizer) from 2000 to 2003. From 1994 to 2000, he was a managing director of the Proprietary Investment Group at the investment bank MeesPierson, part of the Fortis Group, which was a merchant banking group investing in life science companies. Prior to MeesPierson, Robert worked for the investment banks BZW and UBS in the corporate finance groups undertaking M&A, and public and private finance transactions. He is a member of the Board of Directors of Myriad Pharmaceuticals. He holds a LL.B. from Bristol University.


 

About FORMA Therapeutics


 

FORMA Therapeutics unlocks intractable targets to create transformative small molecule therapies. The Company is achieving this by applying its proprietary cell-based screening, structure-guided drug discovery and Diversity Oriented Synthesis (DOS) technologies, which FORMA also uses to discover novel compounds for its partners in indications beyond oncology. FORMA is a global company headquartered in Cambridge, MA with additional research operations in Connecticut and Singapore. www.formatherapeutics.com


 

 


 

Contact: FORMA Therapeutics

Steven Tregay, 617-679-1970

CEO

or

Media Contacts:

MacDougall Biomedical Communications

Douglas MacDougall or Jennifer Conrad, 781-235-3060

[email protected] or [email protected]

 

 

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.